AXL in cancer: a modulator of drug resistance and therapeutic target

被引：34
作者：
Tang, Yaoxiang [1 ]
Zang, Hongjing [1 ]
Wen, Qiuyuan [1 ]
Fan, Songqing [1 ]
机构：
[1] Cent South Univ, Xiangya Hosp 2, Dept Pathol, Changsha 410011, Hunan, Peoples R China
来源：
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2023年 / 42卷 / 01期
基金：
中国国家自然科学基金;
关键词：
AXL; Cancer; Drug resistance; Target therapy; Molecular mechanisms; RECEPTOR TYROSINE KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; BREAST-CANCER; DNA-DAMAGE; GAS6/AXL AXIS; EGFR-TKI; INHIBITION; PROMOTES;
D O I：
10.1186/s13046-023-02726-w
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AXL is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases family (RTKs), and its abnormal expression has been linked to clinicopathological features and poor prognosis of cancer patients. There is mounting evidence supporting AXL's role in the occurrence and progression of cancer, as well as drug resistance and treatment tolerance. Recent studies revealed that reducing AXL expression can weaken cancer cells' drug resistance, indicating that AXL may be a promising target for anti-cancer drug treatment. This review aims to summarize the AXL's structure, the mechanisms regulating and activating it, and its expression pattern, especially in drug-resistant cancers. Additionally, we will discuss the diverse functions of AXL in mediating cancer drug resistance and the potential of AXL inhibitors in cancer treatment.
引用
收藏
页数：14
相关论文
共 113 条
  • [21] Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling
    Dong, Minhai
    Xiao, Qungen
    Hu, Jinyang
    Cheng, Fangling
    Zhang, Po
    Zong, Weifeng
    Tang, Qiaoying
    Li, Xiaopeng
    Mao, Feng
    He, Yue
    Yu, Xingjiang
    Wan, Feng
    Lei, Ting
    Guo, Dongsheng
    Wang, Baofeng
    [J]. CANCER GENE THERAPY, 2020, 27 (12) : 878 - 897
  • [22] Does Axl have potential as a therapeutic target in pancreatic cancer?
    Du, Wenting
    Brekken, Rolf A.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2018, 22 (11) : 955 - 966
  • [23] The miR-625-3p/AXL axis induces non-T790M acquired resistance to EGFR-TKI via activation of the TGF-β/Smad pathway and EMT in EGFR-mutant non-small cell lung cancer
    Du, Wenwen
    Sun, Lin
    Liu, Ting
    Zhu, Jianjie
    Zeng, Yuanyuan
    Zhang, Yang
    Wang, Xueting
    Liu, Zeyi
    Huang, Jian-An
    [J]. ONCOLOGY REPORTS, 2020, 44 (01) : 185 - 195
  • [24] Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
    Engelsen, Agnete S. T.
    Lotsberg, Maria L.
    Abou Khouzam, Raefa
    Thiery, Jean-Paul
    Lorens, James B.
    Chouaib, Salem
    Terry, Stephane
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [25] Giving AXL the axe: targeting AXL in human malignancy
    Gay, Carl M.
    Balaji, Kavitha
    Byers, Lauren Averett
    [J]. BRITISH JOURNAL OF CANCER, 2017, 116 (04) : 415 - 423
  • [26] Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
    Gourley, Charlie
    Balmana, Judith
    Ledermann, Jonathan A.
    Serra, Violeta
    Dent, Rebecca
    Loibl, Sibylle
    Pujade-Lauraine, Eric
    Boulton, Simon J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (25) : 2257 - +
  • [27] Advancement of cancer immunotherapy using nanoparticles-based nanomedicine
    Gowd, Vemana
    Ahmad, Anas
    Tarique, Mohammad
    Suhail, Mohd
    Zughaibi, Torki A.
    Tabrez, Shams
    Khan, Rehan
    [J]. SEMINARS IN CANCER BIOLOGY, 2022, 86 : 624 - 644
  • [28] Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels
    Goyette, Marie-Anne
    Elkholi, Islam E.
    Apcher, Chloe
    Kuasne, Hellen
    Rothlin, Carla, V
    Muller, William J.
    Richard, Darren E.
    Park, Morag
    Gratton, Jean-Philippe
    Cote, Jean-Francois
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (29)
  • [29] The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
    Goyette, Marie-Anne
    Duhamel, Stephanie
    Aubert, Leo
    Pelletier, Ariane
    Savage, Paul
    Thibault, Marie-Pier
    Johnson, Radia Marie
    Carmeliet, Peter
    Basik, Mark
    Gaboury, Louis
    Muller, William J.
    Park, Morag
    Roux, Philippe P.
    Gratton, Jean-Philippe
    Cote, Jean-Francois
    [J]. CELL REPORTS, 2018, 23 (05): : 1476 - 1490
  • [30] Hallmarks of Cancer: New Dimensions
    Hanahan, Douglas
    [J]. CANCER DISCOVERY, 2022, 12 (01) : 31 - 46
12345678910